Reading the tape
NASDAQ: DXCM
DexCom, Inc.
Healthcare · Medical - Devices
Market Cap
$23.17B
52w High
$89.98
52w Low
$54.11
P/E
24.85
Volume
4.87M
Outstanding Shares
385.87M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionHigh confidence
1Y Price: -25.2%Revenue (TTM): 16.15%FCF (TTM): 148.5%P/FCF: 0th pct
What changed
The stock fell 25.2% over the last year. Revenue grew 16.15% over the trailing twelve months. Operating margin moved from 15.25% to 21.45%. Free cash flow grew 148.5% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 0th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 21.45%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
CEOJacob Steven Leach
SectorHealthcare
IndustryMedical - Devices
Employees10,200
IPO dateApr 14, 2005
Valuation
Forward P/E—
EV/EBITDA22.66
Enterprise value$26.37B
Stock splits
Jun 13, 2022↑ Forward
Every 1 shares became 4
Profitability & growth
Revenue growth15.05%
Gross margin61.84%▼0.74%vs FY2024
Operating margin21.45%▲31.46%vs FY2024
ROE30.46%▲11.13%vs FY2024
Analyst consensus
RatingBuy
Target price$80.88▲34.71%
42
Buy
8
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 29, 2026
Q3 FY26 · EPS est $0.60 · Revenue est $1.29B
View
Congressional Activity
Congress Trades in DXCM
STOCK Act disclosures from senators and representatives.
John Boozman
ARsenateRepublicanPurchaseJoint2026-01-26$1,001 - $15,000+19d to disclose